893409-49-9
Chemical Structure
BAY 60-5521
- CAS No.: 893409-49-9
- Formula:C30H37F4NO
- Molecular Weight:503.61
IUPAC Name: (S)-4-cyclohexyl-2-cyclopentyl-3-((S)-fluoro(4-(trifluoromethyl)phenyl)methyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol
InChIKey: BHKIPHICFOJGLD-HOFKKMOUSA-N
SMILES: F[C@@H](C1=CC=C(C=C1)C(F)(F)F)C2=C(C3CCCC3)N=C(CC(C)(C[C@@H]4O)C)C4=C2C5CCCCC5
Biological Activity: BAY 60-5521 is an orally active cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 7 nM. BAY 60-5521 inhibits CETP-mediated transfer of cholesteryl esters from HDL to LDL/VLDL, as well as the transfer of triglycerides from LDL/VLDL to HDL. It dose-dependently increases HDL-C and HDL concentrations, and slightly reduces triglyceride levels. BAY 60-5521 can be used in studies related to dyslipidemia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BAY 60-5521 | BAY 60-5521 is an orally active cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 7 nM. BAY 60-5521 inhibits CETP-mediated transfer of cholesteryl esters from HDL to LDL/VLDL, as well as the transfer of triglycerides from LDL/VLDL to HDL. It dose-dependently increases HDL-C and HDL concentrations, and slightly reduces triglyceride levels. BAY 60-5521 can be used in studies related to dyslipidemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Boettcher MF, et al. Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. British journal of clinical pharmacology. 2012 Feb;73(2):210-8.
- [2]. Weber O, et al. Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling. British journal of clinical pharmacology. 2012 Feb;73(2):219-31.
- [3]. Mantlo NB, et al. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk. Journal of medicinal chemistry. 2014 Jan 09;57(1):1-17.
